HC Wainwright & Co. Reiterates Buy on Karuna Therapeutics, Maintains $300 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Karuna Therapeutics (NASDAQ:KRTX) and maintained a price target of $300.
September 28, 2023 | 11:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Karuna Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $300.
The reiterated 'Buy' rating and maintained price target of $300 by HC Wainwright & Co. indicates a positive outlook for Karuna Therapeutics. This could potentially attract more investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100